Pharmacogenomics of psychiatric disorders.
Pharmacogenomics, the utilization of genetic information to predict outcome of drug treatment (therapeutic and side-effects), holds great promise for clinical medicine. The pharmacotherapy of psychiatric disorders exhibits wide variability in therapeutic response with little scientific guidance for treatment on a patient-by-patient basis. The emerging field of pharmacogenomics holds great potential for refining and optimizing psychopharmacology. Key components for future development of the pharmacogenomics of psychiatric disorders include understanding the mechanism of drug action, identification of candidate genes and their variants, and well-conducted clinical trials. In this article, data from recent studies are examined with particular emphasis on methodological requirements and direction for future research.
Pickar
D
D
Comprehensive NeuroScience Inc., 4701 Willard Avenue, Suite 105, Chevy Chase, MD 20815, USA. dpickar@cnsclinicaltrials.com
Rubinow
K
K
D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics; D011619:Psychotropic Drugs / Q000627:therapeutic use*
D011619:Psychotropic Drugs